Biopharmaceutical companies shoulder substantial expenses throughout the drug development journey, from research and development to manufacturing and clinical trials. Often overlooked are the additional costs incurred through customs duties and value-added tax (VAT) charges on imports. In the pre-revenue phase, these expenses may be perceived as inevitable, yet there exist untapped opportunities for savings.
Watch our recorded webcast, in which we delved into strategies to alleviate the burden of import tariffs and VAT costs. By implementing effective cost mitigation strategies, biopharma companies could not only reduce expenses but also enhance cash flow, paving the way for sustained growth and innovation.
